Patent ID: 9624242
Date: 2017-04-18
CPC Classifications: A61P,C07B,C07C,C07D

Claim:
1. A method of treating cancer comprising administration of a therapeutically effective amount of a crystalline citrate salt of 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene which shows on X-ray diffraction a peak on the 2theta scale at 22.4°±0.5° or a pharmaceutical composition comprising the salt to a patient in need thereof, wherein the cancer is glioblastoma multiforme, chronic myelomonocytic leukemia or Hodgkin's disease.